The FDA approved mFlusiva, the first mRNA flu vaccine, for adults 50 and older. In a large clinical trial, mFlusiva was about 27 percent more effective than a standard-dose flu vaccine at preventing ...
Hosted on MSN
The FDA approved the first mRNA flu vaccine for use in older adults. Here’s what to know
For older adults, the flu vaccine could look a little different this year. Last week, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 and ...
For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...
Add Yahoo as a preferred source to see more of our stories on Google. Lead medical assistant Yiseli Dominguez administers a flu vaccine to a patient at the Esperanza Health Centers Brighton Park North ...
Key Takeaway: The FDA’s approval of mFLUSIVA may indicate increased commercial and strategic value of mRNA vaccine patents. On August 5, 2026, Moderna announced that the U.S. Food and Drug ...
Now is around the time when flu season usually starts to pick up — except this year, cases have been rising since late summer ...
The Food and Drug Administration has approved the first messenger RNA-based vaccine for seasonal flu, after rejecting it earlier this year. Moderna’s new seasonal flu vaccine using mRNA technology for ...
Moderna’s mFlusiva is the first mRNA flu vaccine approved in the U.S., but strain-selection timing and vaccine skepticism could shape its market impact. The illustration depicts the lipid-nanoparticle ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA on Aug. 5, 2026 approved a new mRNA-based flu vaccine. (Melissa Phillip/AP) After months of regulatory questioning, the ...
The U.S. Food and Drug Administration has approved a new flu vaccine, Moderna's mFlusiva, marking the public release of the first non-COVID-related mRNA vaccine in the U.S. Moderna's vaccine was ...
The FDA has approved Moderna’s mFlusiva, also known as mRNA-1010, for preventing influenza caused by the virus strains included in the vaccine. The approval covers adults ages 50 and older, although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results